CA3025461A1 - Proteines klotho recombinees therapeutiques et compositions et methodes comprenant celles-ci - Google Patents

Proteines klotho recombinees therapeutiques et compositions et methodes comprenant celles-ci Download PDF

Info

Publication number
CA3025461A1
CA3025461A1 CA3025461A CA3025461A CA3025461A1 CA 3025461 A1 CA3025461 A1 CA 3025461A1 CA 3025461 A CA3025461 A CA 3025461A CA 3025461 A CA3025461 A CA 3025461A CA 3025461 A1 CA3025461 A1 CA 3025461A1
Authority
CA
Canada
Prior art keywords
protein
klotho
seq
decline
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3025461A
Other languages
English (en)
Inventor
Joseph F. Tarsio
Dinesh RATURI
James R. PLANTE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Klotho Therapeutics Inc
Original Assignee
Klotho Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klotho Therapeutics Inc filed Critical Klotho Therapeutics Inc
Publication of CA3025461A1 publication Critical patent/CA3025461A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
    • C12N9/0028—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
    • C12N9/003—Dihydrofolate reductase [DHFR] (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y105/00—Oxidoreductases acting on the CH-NH group of donors (1.5)
    • C12Y105/01—Oxidoreductases acting on the CH-NH group of donors (1.5) with NAD+ or NADP+ as acceptor (1.5.1)
    • C12Y105/01003—Dihydrofolate reductase (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/01—Acid-ammonia (or amine)ligases (amide synthases)(6.3.1)
    • C12Y603/01002—Glutamate-ammonia ligase (6.3.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Abstract

L'invention concerne des protéines Klotho recombinées et des variants de celles-ci, des acides nucléiques codant pour celles-ci, des lignées cellulaires et des cultures en suspension exprimant celles-ci, ainsi qu'un procédé de fabrication et d'administration de celles-ci. Les protéines comprennent des éléments permettant de prolonger la solubilité ou la demi-vie comme des marqueurs de glycosylation et de protéines de fusion. Les protéines présentent au moins 85 % d'identité de séquences d'acides aminés avec une partie de l'isoforme 1 de l'alpha-Klotho humaine. Les protocoles de traitement comprennent la détermination du taux de Klotho soluble dans le sérum chez un sujet, le calcul d'une dose de la protéine qui soit suffisante pour accroître le taux de Klotho soluble dans le sérum chez le sujet jusqu'à un taux prédéfini, l'administration au sujet de la dose de protéine, tel que par une seule injection ou une injection progressive, la détermination d'une vitesse de diminution du taux de protéine Klotho dans le sérum du sujet après l'administration de la première dose, le calcul d'un instant et d'une quantité d'une dose suivante de la protéine Klotho, et l'administration au sujet de la dose suivante de la protéine Klotho.
CA3025461A 2016-06-02 2017-06-02 Proteines klotho recombinees therapeutiques et compositions et methodes comprenant celles-ci Pending CA3025461A1 (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662344743P 2016-06-02 2016-06-02
US62/344,743 2016-06-02
US201662375046P 2016-08-15 2016-08-15
US62/375,046 2016-08-15
US201662401600P 2016-09-29 2016-09-29
US62/401,600 2016-09-29
US201662425237P 2016-11-22 2016-11-22
US62/425,237 2016-11-22
US201762456318P 2017-02-08 2017-02-08
US62/456,318 2017-02-08
PCT/US2017/035755 WO2017210607A1 (fr) 2016-06-02 2017-06-02 Protéines klotho recombinées thérapeutiques et compositions et méthodes comprenant celles-ci

Publications (1)

Publication Number Publication Date
CA3025461A1 true CA3025461A1 (fr) 2017-12-07

Family

ID=60477890

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3025461A Pending CA3025461A1 (fr) 2016-06-02 2017-06-02 Proteines klotho recombinees therapeutiques et compositions et methodes comprenant celles-ci

Country Status (9)

Country Link
EP (1) EP3464608A4 (fr)
JP (2) JP2019526272A (fr)
KR (2) KR102570250B1 (fr)
CN (2) CN109219663A (fr)
AU (1) AU2017272349B2 (fr)
BR (1) BR112018073909A2 (fr)
CA (1) CA3025461A1 (fr)
MX (2) MX2018014753A (fr)
WO (1) WO2017210607A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201900007446A1 (it) 2019-05-29 2020-11-29 Giuseppe Castellano Composizione comprendente citrato e carnitina in grado di attivare la produzione della proteina klotho

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019005687A (es) * 2016-11-22 2019-09-05 Klotho Therapeutics Inc Proteinas klotho recombinantes novedosas y composiciones y metodos que involucran a las mismas.
CN108333355B (zh) * 2018-02-01 2020-05-26 黄曙 Klotho蛋白在制备诊断胃肠道间质瘤危险度的试剂中的用途
CN108384747A (zh) * 2018-03-05 2018-08-10 安徽省农业科学院园艺研究所 表达狂犬抗体的cho细胞无血清悬浮培养方法
CN109251896A (zh) * 2018-08-13 2019-01-22 中山大学 一株高表达hKLs-his蛋白的细胞株及其制备方法和应用
WO2020160617A1 (fr) * 2019-02-05 2020-08-13 Helium 3 Biotech Pty Ltd Composition de modulation de l'expression et de la distribution de protéines membranaires et son procédé d'utilisation
RU2712770C1 (ru) * 2019-05-21 2020-01-31 Всеволод Викторович Мелехин Способ ингибирования роста опухолевых клеток
US11891615B2 (en) 2020-06-10 2024-02-06 Gail Marion Humble Process to produce Klotho protein in vitro
CN112195165A (zh) * 2020-10-15 2021-01-08 广东药科大学 一种抗衰老分泌型Klotho蛋白及其编码基因、重组表达载体与应用
CN114487218B (zh) * 2020-10-23 2023-11-14 北京红惠新医药科技有限公司 β-烟酰胺单核苷酸的分析方法
CN112915193B (zh) * 2021-03-05 2022-09-13 南方医科大学南方医院 Kp-1在制备治疗慢性肺病的药物中的用途
CN113444730A (zh) * 2021-03-17 2021-09-28 昆明市延安医院 一种原发性肝细胞klotho基因转导干细胞筛选构建方法
CN113215199A (zh) * 2021-04-29 2021-08-06 广州博识生物科技有限公司 一种Klotho+/-基因缺失斑马鱼
EP4340868A1 (fr) * 2021-05-21 2024-03-27 Universitat Autònoma de Barcelona Variant d'épissage sécrété de klotho pour le traitement de troubles osseux
CN113409306A (zh) * 2021-07-15 2021-09-17 推想医疗科技股份有限公司 一种检测装置、训练方法、训练装置、设备和介质
WO2023172444A2 (fr) * 2022-03-08 2023-09-14 Mayo Foundation For Medical Education And Research Agents sénothérapeutiques et polypeptides alpha-klotho
WO2023218445A1 (fr) * 2022-05-08 2023-11-16 Ichilov Tech Ltd. Dérivés de klotho à structure modifiée

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027885A1 (fr) * 1998-11-05 2000-05-18 Kyowa Hakko Kogyo Co., Ltd. Nouveau popypeptide chimerique
ES2354610T5 (es) * 2002-12-23 2020-09-14 Bristol Myers Squibb Co Mejora de la calidad del producto en procedimientos de cultivo de células de mamífero para la producción de proteína
TW200936156A (en) * 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
CN102861343A (zh) * 2012-10-17 2013-01-09 南方医科大学 分泌型Klotho在制备治疗慢性肾脏病的药物中的应用
MY184699A (en) * 2014-04-16 2021-04-18 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201900007446A1 (it) 2019-05-29 2020-11-29 Giuseppe Castellano Composizione comprendente citrato e carnitina in grado di attivare la produzione della proteina klotho
WO2020239459A1 (fr) 2019-05-29 2020-12-03 Iperboreal Pharma Srl Composition comprenant du citrate et de la carnitine, apte à activer la production de la protéine klotho

Also Published As

Publication number Publication date
KR20190015711A (ko) 2019-02-14
AU2017272349B2 (en) 2022-12-01
AU2017272349A1 (en) 2018-11-22
MX2023008626A (es) 2023-08-08
JP2023123565A (ja) 2023-09-05
JP2019526272A (ja) 2019-09-19
KR102570250B1 (ko) 2023-08-29
MX2018014753A (es) 2019-06-17
EP3464608A4 (fr) 2020-01-29
CN109219663A (zh) 2019-01-15
EP3464608A1 (fr) 2019-04-10
KR20230125857A (ko) 2023-08-29
BR112018073909A2 (pt) 2019-02-26
CN116478907A (zh) 2023-07-25
WO2017210607A1 (fr) 2017-12-07

Similar Documents

Publication Publication Date Title
AU2017272349B2 (en) Therapeutic recombinant klotho proteins and compositions and methods involving the same
US11932676B2 (en) Recombinant klotho proteins and compositions and methods involving same
US20210121571A1 (en) Methods of reducing aggregation of il-1ra
EP3298140B1 (fr) Compositions pour le traitement d'états de calcification pathologique, et méthodes les utilisant
JP7290340B2 (ja) クロトータンパク質レベルを評価および改善するための製品および方法
US20230227800A1 (en) Compositions for treating ectopic calcification disorders, and methods using same
AU2018270925A1 (en) Recombinant human acid alpha-glucosidase
JP2019524740A (ja) Ｃｒｅｂｂｐ関連癌の治療法
EP3493829B1 (fr) Compositions et méthodes de prévention d'accident vasculaire cérébral chez des patients atteints de drépanocytose pédiatrique
EP2678353B1 (fr) Dérivés de igfbp-3 et utilisations de ceux-ci
US20210371839A1 (en) Products and Methods for Assessing and Increasing Klotho Protein Levels
WO2015103026A2 (fr) Traitement des troubles neurologiques
Wu Perturbed Brain Energy Metabolism in Alzheimer’s Disease and Diabetes
US20200115427A1 (en) Method for diagnosing or treating pulmonary fibrosis using s100a13 protein
WO2018088464A1 (fr) Agent thérapeutique pour infarctus cérébral
METZE Darier disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220601

EEER Examination request

Effective date: 20220601

EEER Examination request

Effective date: 20220601

EEER Examination request

Effective date: 20220601

EEER Examination request

Effective date: 20220601